Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on: October 17,2023

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on:October 17,2023

To improve a promising cancer drug, cut it in half

by Ian Haydon,University of Washington School of MedicineNeoleukin-2/15 can be split into two fragments that reconstitute its activity when combined. a, Splitting strategy for Neo-2/15. Structur

Updated on: January 08,2024

To improve a promising cancer drug, cut it in half

by Ian Haydon,University of Washington School of MedicineNeoleukin-2/15 can be split into two fragments that reconstitute its activity when combined. a, Splitting strategy for Neo-2/15. Structur

Updated on:January 08,2024

Tracking genes to fight breast cancer

byLeiden UniversityMicroscope image of moving breast cancer cells leaving a track. Koedoot: "We switched of certain proteins and then looked to see if the pathways changed." Credit: Es

Updated on: December 20,2023

Tracking genes to fight breast cancer

byLeiden UniversityMicroscope image of moving breast cancer cells leaving a track. Koedoot: "We switched of certain proteins and then looked to see if the pathways changed." Credit: Es

Updated on:December 20,2023

Fertility preservation measures do not appear to increase the risk of breast cancer recurrence

byKarolinska InstitutetCancer-Specific Survival in the Cohort. FP indicates fertility preservation. Credit:JAMA OncologyDOI: 10.1001/jamaoncol.2022.3677Women with a breast cancer dia

Updated on: December 19,2023

Fertility preservation measures do not appear to increase the risk of breast cancer recurrence

byKarolinska InstitutetCancer-Specific Survival in the Cohort. FP indicates fertility preservation. Credit:JAMA OncologyDOI: 10.1001/jamaoncol.2022.3677Women with a breast cancer dia

Updated on:December 19,2023

Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on: December 22,2023

Saliva test shows promise for earlier and easier detection of mouth and throat cancer

byElsevierAcoustofluidic exosome isolation chip for salivary exosome isolation. The microfluidic channel is shown by red dye solution and the coin demonstrates the size of the chip. Two pairs of

Updated on:December 22,2023

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on: October 12,2023

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on:October 12,2023

Mayo Clinic Minute: Learning the 'ABCDEs' of melanoma

by Alex OsiadaczMelanoma. Credit: Wikimedia Commons/National Cancer InstituteMelanoma is a type of skin cancer that develops in cells that produce your skin's pigment. Regular skin checks can help

Updated on: December 18,2023

Mayo Clinic Minute: Learning the 'ABCDEs' of melanoma

by Alex OsiadaczMelanoma. Credit: Wikimedia Commons/National Cancer InstituteMelanoma is a type of skin cancer that develops in cells that produce your skin's pigment. Regular skin checks can help

Updated on:December 18,2023

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on: October 15,2023

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on:October 15,2023

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on: October 17,2023

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on:October 17,2023

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on: December 21,2023

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on:December 21,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on: October 12,2023

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on:October 12,2023

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was

Updated on: December 17,2023

Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

by Impact JournalsExpression of lncRNA MVIH in CC tumor as compared to marginal non-tumor tissues. Credit:Genes & Cancer(2022). DOI: 10.18632/genesandcancer.224A new research paper was

Updated on:December 17,2023